THE Therapeutic Goods Administration has announced approval of an eighth indication for Bristol-Myers Squibb's immuno-oncology therapy, Opdivo (nivolumab), namely for advanced inoperable bladder cancer under certain conditions.
Monash University and Eastern Health Medical Oncologist and Professor of Medicine Professor Ian Davis was quoted as saying, "The registration of OPDIVO for the treatment of advanced bladder cancer in Australia is a positive step forward as there have been few advancements in treatment of this disease over the last few decades."
See the full PI at medicines.org.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 16 Feb 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Feb 18
